Program
Triamcinolone Acetonide
Also written as “triamcinolone acetonide”, “SC CLS-TA” and “suprachoroidal CLS-TA”.
Its studies are mostly in Macular Edema · Uveitis · Diabetes Mellitus · Keloid · Pain, led by 12 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Clearside Biomedical | 70 open or running | phase 3since Oct 28, 2015 | Feb 5, 2013 | none ahead |
| Pacira BioSciences | 21 open or running | phase 3since Feb 13, 2024 | Feb 13, 2024 | Dec 2026phase 3 · NCT06269705 |
| Sanofi | 20 open or running | phase 3since Jun 26, 2006 | Jun 26, 2006 | none ahead |
| Alcon | 10 open or running | phase 3since Sep 19, 2007 | Sep 19, 2007 | none ahead |
| Biosplice Therapeutics | 10 open or running | phase 1since Oct 6, 2020 | Oct 6, 2020 | none ahead |
| GlaxoSmithKline | 10 open or running | phase 1since Oct 31, 2013 | Oct 31, 2013 | none ahead |
| Harrow | 11 open or running | phase 3since Sep 14, 2026 | Sep 14, 2026 | Dec 2026phase 3 · NCT07832552 |
| Merck | 10 open or running | phase 2since Jun 4, 2008 | Jun 4, 2008 | none ahead |
| Novartis | 10 open or running | phase 3since Oct 19, 2005 | Oct 19, 2005 | none ahead |
| Oxular | 10 open or running | phase 2since Aug 20, 2022 | Aug 20, 2022 | none ahead |
| PT. Prodia Stem Cell Indonesia | 10 open or running | phase 2since Mar 26, 2020 | Mar 26, 2020 | none ahead |
| SurModics | 10 open or running | phase 1since Jun 4, 2009 | Jun 4, 2009 | none ahead |
Also a collaborator on its studies: qlt-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 6 studies since Oct 19, 2005.
- Oct 31, 2013GlaxoSmithKline's first study: phase 1 study in FibrosisNew to GlaxoSmithKlineGlaxoSmithKline · NCT01978301 · 9 enrolled · United Kingdom
- Oct 28, 2015Phase 3 study in UveitisClearside Biomedical · NCT02595398 · 160 enrolled · United States, India, Israel
- Oct 25, 2016Phase 2 study in Diabetes MellitusClearside Biomedical · NCT02949024 · 20 enrolled · United States
- Nov 30, 2016Phase 3 study in Macular EdemaClearside Biomedical · NCT02980874 · 460 enrolled · United States, Australia, Austria and more
- Mar 27, 2017Phase 3 study in UveitisClearside Biomedical · NCT03097315 · 38 enrolled · United States
- Apr 20, 2017Phase 2 study in Diabetes MellitusClearside Biomedical · NCT03126786 · 71 enrolled · United States
- Jun 28, 2017Phase 3 study in Macular EdemaClearside Biomedical · NCT03203447 · 325 enrolled · United States, Australia, Hungary and more
- Oct 18, 2017Phase 3 study in Rhinitis, Allergic, PerennialSanofi · NCT03317015 · 260 enrolled
- Mar 26, 2020PT. Prodia Stem Cell Indonesia's first study: phase 2 study in KeloidNew to PT. Prodia Stem Cell IndonesiaPT. Prodia Stem Cell Indonesia · NCT04326959 · 24 enrolled
- Oct 6, 2020Biosplice Therapeutics's first study: phase 1 study in Drug-Drug InteractionNew to Biosplice TherapeuticsBiosplice Therapeutics · NCT04598542 · 40 enrolled · United States
- Aug 20, 2022Oxular's first study: phase 2 study in Diabetic Macular EdemaNew to OxularOxular · NCT05512962 · 25 enrolled · United States
- Feb 13, 2024Pacira BioSciences's first study: phase 3 study in Glenohumeral OsteoarthritisNew to Pacira BioSciencesPacira BioSciences · NCT06269705 · 150 enrolled · United States
- May 7, 2025Phase 2 study in Osteoarthritis, HipPacira BioSciences · NCT06977568 · 1 enrolled · United States
- Sep 14, 2026Harrow's first study: phase 3 study in Postoperative Ocular InflammationNew to HarrowHarrow · NCT07832552 · 250 planned · United States
Ahead
- Dec 2026Primary completion: phase 3 study in Postoperative Ocular InflammationHarrow · NCT07832552
- Dec 2026Primary completion: phase 3 study in Glenohumeral OsteoarthritisPacira BioSciences · NCT06269705
TargetBeta
“Glucocorticoid receptor agonist”ChEMBL 37, by rule
Other programs on NR3C1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Dexamethasonerule | AbbVie | phase 4 | 174 |
| Budesoniderule | AstraZeneca | phase 4 | 167 |
| fluticasone furoaterule | GlaxoSmithKline | phase 4 | 97 |
| Prednisonerule | Johnson & Johnson | phase 4 | 65 |
| Beclomethasonerule | Chiesi Farmaceutici | phase 4 | 46 |
| Prednisolonerule | Sanofi | phase 4 | 34 |
| betamethasone dipropionaterule | LEO Pharma | phase 4 | 27 |
| Methylprednisolonerule | Pfizer | phase 4 | 23 |
| dexamethasone phosphaterule | eyegate-pharmaceuticals-inc | phase 4 | 21 |
| vamorolonerule | reveragen-biopharma-inc | phase 4 | 11 |
| Betamethasonerule | LEO Pharma | phase 4 | 9 |
| Triamcinolonerule | research-insight-llc | phase 4 | 5 |
Studies
All 20 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07832552Postoperative Ocular Inflammation · United States | 3 | By invitation | Harrow | Dec 2026 | 250 |
| NCT06977568Osteoarthritis, Hip · United States | 2 | Terminated | Pacira BioSciences | Oct 16, 2025 | 1 |
| NCT06269705Glenohumeral Osteoarthritis · United States | 3 | Active, not recruiting | Pacira BioSciences | Dec 2026 | 150 |
| NCT05512962Diabetic Macular Edema · United States | 2 | Completed | Oxular | Nov 30, 2023 | 25 |
| NCT04598542Drug-Drug Interaction · United States | 1 | Completed | Biosplice Therapeutics | Dec 22, 2020 | 40 |
| NCT04326959Keloid | 2 | UNKNOWN | PT. Prodia Stem Cell Indonesia | Sep 8, 2020 | 24 |
| NCT03317015Rhinitis, Allergic, Perennial | 3 | Completed | Sanofi | Jul 10, 2017 | 260 |
| NCT03203447Macular Edema · United States, Australia, Hungary and more | 3 | Terminated | Clearside Biomedical | Dec 18, 2018 | 325 |
| NCT03126786Diabetes Mellitus · United States | 2 | Completed | Clearside Biomedical | Apr 17, 2018 | 71 |
| NCT03097315Uveitis · United States | 3 | Completed | Clearside Biomedical | Jan 24, 2018 | 38 |
| NCT02980874Macular Edema · United States, Australia, Austria and more | 3 | Terminated | Clearside Biomedical | Dec 10, 2018 | 460 |
| NCT02949024Diabetes Mellitus · United States | 2 | Completed | Clearside Biomedical | Oct 17, 2017 | 20 |
| NCT02595398Uveitis · United States, India, Israel | 3 | Completed | Clearside Biomedical | Jan 18, 2018 | 160 |
| NCT01978301Fibrosis · United Kingdom | 1 | Terminated | GlaxoSmithKline | Feb 5, 2015 | 9 |
| NCT01789320Uveitis · United States | 2 | Completed | Clearside Biomedical | Mar 2015 | 11 |
| NCT00915837Diabetic Macular Edema · United States | 1 | Completed | SurModics | Apr 2009 | 31 |
| NCT00692614Macular Edema | 2 | Terminated | Merck | Nov 2008 | 2 |
| NCT00532415Vitrectomy | 3 | Completed | Alcon | Sep 2007 | 60 |
| NCT00344942Rhinitis · France | 3 | Terminated | Sanofi | Apr 2007 | 77 |
| NCT00242580Macular Degeneration · United States | 3 | Completed | Novartis | Jan 2008 | 111 |
How it is read
Names in the registry
- “triamcinolone acetonide”, 4 entries
- “Triamcinolone Acetonide”, 2 entries
- “SC CLS-TA”, 2 entries
- “suprachoroidal CLS-TA”, 2 entries
- “Triamcinolone acetonide”, 2 entries
Conditions, from the studies’ own filings
- Macular Edema, 5 studies
- Uveitis, 3 studies
- Diabetes Mellitus, 2 studies
- Keloid, 2 studies
- Pain, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.